Abstract：Objective To compare the clinical features and follow-up results of systemic lupus erythematosus (SLE) between boys and girls. Methods A retrospective analysis was performed for the clinical data of 79 children (18 boys and 61 girls), aged ≤ 14 years, who were diagnosed with SLE from 2008 to 2018. The boys and the girls were compared in terms of initial and major clinical symptoms, injury of organs/systems, related laboratory markers, and follow-up results. Results As for the initial and non-initial symptoms, fever had the highest incidence rate in the boys, while facial erythema had the highest incidence rate in the girls. The boys tended to develop renal injury and hematological damage (P P P 80%) of anti-nuclear antibody, dsDNA, complement C3, and erythrocyte sedimentation rate in both boys and girls (P > 0.05). The boys had a significantly higher disease activity than the girls at the first visit and in year 9 of follow-up (P Conclusions There are differences in clinical features, several laboratory markers, and prognosis between boys and girls with SLE. Boys tend to have a high severity at disease onset, develop renal injury and hematological damage, and have poor long-term prognosis, while girls tend to have joint involvement.
CHEN Wei-Na,LUO Xiu,SI You-Hua et al. Clinical features and follow-up results of boys and girls with systemic lupus erythematosus: a comparative analysis[J]. CJCP, 2020, 22(2): 164-170.
Oku K, Atsumi T. Systemic lupus erythematosus:nothing stale her infinite variety[J]. Mod Rheumatol, 2018, 28(5):758-765.
[2]
Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus:a systematic review of epidemiological studies[J]. Rheumatology (Oxford), 2017, 56(11):1945-1961.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9):1725.
[7]
Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE[J]. Arthritis Rheum, 1992, 35(6):630-640.
[8]
Couture J, Silverman ED. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus[J]. Curr Opin Rheumatol, 2016, 28(5):488-496.
Artim-Esen B, Şahin S Çene E, et al. Comparison of disease characteristics, organ damage, and survival in patients with juvenile-onset and adult-onset systemic lupus erythematosus in a combined cohort from 2 tertiary centers in Turkey[J]. J Rheumatol, 2017, 44(5):619-625.
[11]
Molina-Ruiz AM, Lasanta B, Barcia A, et al. Drug-induced systemic lupus erythematosus in a child after 3 years of treatment with carbamazepine[J]. Australas J Dermatol, 2017, 58(1):e20-e22.
Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis:the SHARE initiative[J]. Ann Rheum Dis, 2017, 76(12):1965-1973.
[14]
Lee PY, Yeh KW, Yao TC, et al. The outcome of patients with renal involvement in pediatric-onset systemic lupus erythematosus-a 20-year experience in Asia[J]. Lupus, 2013, 22(14):1534-1540.
[15]
Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus[J]. Medicine (Baltimore), 2006, 85(3):147-156.
